Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer

BMC Urology

Technical Advance

Shohei Shimajiri¹  Tatsuhiko Kubo²  Naohiro Fujimoto³  Masahiro Matsumoto³  Hideo Shinsaka³  Tetsuro Matsumoto³ 

[1] Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, 807-8555, Kitakyushu, Japan;Department of Public Health, School of Medicine, University of Occupational and Environmental Health, 807-8555, Kitakyushu, Japan;Department of Urology, School of Medicine, University of Occupational and Environmental Health, 807-8555, Kitakyushu, Japan;

关键词: Androgen Deprivation Therapy;    Localize Prostate Cancer;    Prostatectomy Specimen;    Japanese Male;    Primary Androgen Deprivation Therapy;   

DOI  :  10.1186/1471-2490-11-7

 received in 2011-01-21, accepted in 2011-05-14,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundPrimary androgen deprivation therapy (ADT) is a treatment option not only for advanced but also for localized prostate cancer. However, the appropriate duration for primary ADT for localized prostate cancer has not been defined and few studies have addressed this issue. In this study, we aimed to determine the appropriate duration of ADT for localized prostate cancer.MethodsSixty-eight consecutive patients with localized prostate cancer who underwent a prostatectomy following neoadjuvant ADT were retrospectively reviewed. Factors associated with pT0, which is regarded as serious cancer cell damage or elimination, were investigated.ResultsOf the 68 males, 24 (35.3%) were classified as pT0. The median duration of neoadjuvant ADT in the pT0 and non-pT0 groups was 9 months and 7.5 months, respectively (p = 0.022). The duration of neoadjuvant ADT from when PSA reached < 0.2 ng/ml to surgery was longer in the pT0 group than that in the non-pT0 group (median 5 months against 3 months, p = 0.011). pT0 was achieved in 5 of 6 patients (83.3%) who received ADT for ≥10 months after PSA reached < 0.2 ng/ml. No other clinical characteristics predicted conversion to pT0.ConclusionsContinuous ADT for ≥10 months after PSA reached < 0.2 ng/ml induced serious prostate cancer cell damage in most patients (> 80%) and may be sufficient to treat localized prostate cancer.

【 授权许可】

CC BY   
© Fujimoto et al; licensee BioMed Central Ltd. 2011